Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 18/20 | 0.87 |
| ▸ | HSP90AB1 | P08238 | 18/20 | 0.87 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.76 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2604977 | 0.93 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL1864541 | 0.87 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL23819778 | 0.86 | HSP90AA1 (0.81) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL4854328 | 0.86 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ERBB2 | |
| SCHEMBL1859519 | 0.83 | HSP90AA1 (0.80) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL1864700 | 0.83 | HSP90AA1 (0.80) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL23450478 | 0.81 | HSP90AA1 (0.79) | HSP90AA1HSP90AB1ERBB2 | |
| SCHEMBL27584530 | 0.81 | HSP90AA1 (0.77) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL1964321 | 0.80 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL30583135 | 0.80 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ERBB2HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135290-A1 | MACROCYCLIC PRODRUG COMPOUNDS USEFUL AS THERAPEUTICS | ONCOSYNERGY, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8450305-B2 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2013-05-28 | — | — | US | disclosed |
| US-20120077775-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-03-29 | — | — | US | disclosed |
| US-20110190237-A1 | Macrocyclic Prodrug Compounds Useful as Therapeutics | NEXGENIX PHARMACEUTICALS (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077775-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885ERBB2 915/4885 |
| US-20110190237-A1 | Macrocyclic Prodrug Compounds Useful as Therapeutics | ADCYAP1R1, CYP19A1, THOP1 | HSP90AA1 4055/4885HSP90AB1 3953/4885ERBB2 982/4885 |
| US-20140135290-A1 | MACROCYCLIC PRODRUG COMPOUNDS USEFUL AS THERAPEUTICS | ADCYAP1R1, CYP19A1, THOP1 | HSP90AA1 4055/4885HSP90AB1 3953/4885ERBB2 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.